Skip to contentN
Niagen Bioscience, Inc.
N
NAGENiagen Bioscience, Inc. Q2 2021 · 10-Q
Revenue$17.70M$17.70M+15.8% vs Q2 2020 Net Income-$5.57M-$5.57MN/M vs Q2 2020 EPS Diluted-$0.08-$0.08N/M vs Q2 2020 Gross Profit$10,810,000+18.9% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Niagen Bioscience, Inc. · CIK 1386570 · Engraved from SEC EDGAR
Operating Cash Flowderived-$7,895,000N/M Margins · derivedGross margin61.1%+1.6 pt vs Q2 2020
Operating margin-31.4%−7.3 pt vs Q2 2020
Net margin-31.4%−7.2 pt vs Q2 2020
ended Jun 30, 2021 · filed Aug 3, 2021 · 34 d after period end